QualityStocksNewsBreaks Archives - Page 327 of 1387

TuesdayOct 18, 2022 12:40 pm

QualityStocksNewsBreaks – Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Reports Assay Results from Iska Iska Drills

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, has been conducting an ongoing drilling program at its Iska Iska silver-tin polymetallic project and is reporting on two diamond drill holes. According to the announcement, drill hole DSB-36 collared 400m southeast of the Santa Barbara adit, tested the extension of the core of the high-grade feeder zone at Santa Barbara while hole DSB-34 tested the potential southwest limits of the high-grade feeder zone. Eloro noted that so far 118 drill holes have…

TuesdayOct 18, 2022 12:32 pm

QualityStocksNewsBreaks – Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) CEO Joins Hercules Electric Mobility CEO to Discuss New Deal

Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF), a clean-technology company developing transformative power conversion technologies and control system solutions for next-generation EVs and electrical systems, has signed an agreement with Hercules Electric Mobility to bring customizable electric mobility products to market. Leaders from the two companies — HLRTF CEO Don Currie and Hercules Electric Mobility CEO James Breyer — discussed the partnership on a recent Proactive interview with host Steve Darling, noting that the partnership is aimed at integrating the latest technologies into new, innovative products and accelerating the path to market. To view the full interview, visit https://ibn.fm/BzwI1 To view…

MondayOct 17, 2022 2:34 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Featured in BioWorld(TM) MedTech Article

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed an innovative platform for heart attack detection anytime, anywhere, was featured in a recent BioWorld(TM) MedTech article. “HeartBeam Inc. has been awarded a patent for what it called ‘the first and only’ 3D-vector, 12-lead ECG platform for heart attack detection, this in conjunction with a credit card-sized device inside a consumer’s wallet for personal monitoring,” the piece reads. “The company said it can record and remotely transmit a set of cardiac signals to a physician for review so that patients at high risk of cardiac arrest are not left alone…

MondayOct 17, 2022 1:35 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Continues Focus to Create the Best Psychedelic Therapies for Patients

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. “The in-human trial is critical to the company’s continued development of CYB003, a deuterated psilocybin analog that Cybin believes has potential to successfully address the challenges and limitations of oral psilocybin. According to the company’s preclinical research, CYB003 achieved less variability in plasma levels, along with faster onset of action, improved brain penetration, and shorter duration…

MondayOct 17, 2022 1:05 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Anticipating 2023 IND Application for Secondary Portfolio Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is currently conducting a potentially pivotal global phase 2 clinical trial in humans to test the effectiveness of its anti-glioblastoma (“GBM”) drug candidate – Berubicin. Testing of Berubicin resulted in a notable success with evidence of improved survival among a dozen safety trial participants recruited by the drug’s original developer over 15 years ago. In its annual stockholder meeting, the company also provided an update for its secondary drug portfolio WP1244. The anthracycline-based substance, being evaluated for the treatment of brain cancers, ovarian and lymphomas, “has produced a new derivative as WP1874 with…

MondayOct 17, 2022 12:54 pm

QualityStocksNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Designed to Mitigate Short- and Long-Term Effects of mTBI

Odyssey Health (OTC: ODYY) early last year acquired PRV-002, a drug candidate for concussed patients to mitigate both short-term and long-term consequences of concussion. Concussion or mTBI “is caused by a jolt, blow or force to the head that changes the brain’s function. This change often results in myriad consequences ranging from emotional and somatic changes to cognitive impairment and physical symptoms… In most cases, concussion symptoms resolve within a few days or weeks as the damaged pathways rebuild and strengthen through repetition, use and cleanup of cell debris. However, there has been growing concern that mTBI may be associated…

MondayOct 17, 2022 11:22 am

QualityStocksNewsBreaks — Cepton Technologies Inc. (NASDAQ: CPTN) Partners with LidarSwiss to Create Nano P60 System

Cepton Technologies (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, announced that LidarSwiss Solutions GmbH is deploying its Sora(TM) lidar technology in the company’s drone-based mapping and analytics solution, which is available for infrastructure management and engineering design applications. The full Nano P60 system is on display at the INTERGEO event, held Oct. 18–20, 2022, in Germany. Based in Switzerland, LidarSwiss provides high-performance unmanned aerial vehicle (“UAV”)-based lidar solutions that feature high-fidelity mapping and real-time processing, a key solution for engineers, forestry managers and urban planners. The Nano P60 platform has been used to map and analyze…

MondayOct 17, 2022 9:30 am

QualityStocksNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Continues to Broaden Reach with Fr8App B2B Marketplace

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), an over-the-road shipping technology innovator, has developed an AI-powered marketplace solution for optimizing and automating the supply chain process to help keep trucks moving with minimal obstacles. “The company’s Fr8App B2B marketplace is its flagship product in a suite powered by AI and machine learning technology that helps connect shippers with qualified carriers as a real-time broker portal… In the company’s Q2 2022 financial report, Fr8Tech noted that quarterly revenue for the period ended June 30 grew 60% over the Q1 report and was up 45% for the period YoY, establishing a new record for…

FridayOct 14, 2022 12:27 pm

QualityStocksNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Marks Milestone Toward Unique and Uncompromising EV Experience

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, recently announced a partnership with Watergen Inc., an Israel-based company building technology and equipment that create drinking water from the air, to develop and equip Mullen’s portfolio of EVs with technology that will produce fresh drinking water for in-vehicle consumer and commercial application. “Watergen’s technology of ‘air to clean drinking water’ for vehicles can generate a fresh supply of hot and drinking water for vehicle occupants. This technology is envisioned for Mullen’s fleet of EV cargo vans and can be utilized in both commercial and recreational vehicle settings. The air-to-water…

FridayOct 14, 2022 12:05 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Executes on Several Clinical, Operational Advancements in Pursuit of GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently released its financial results for the second quarter of the fiscal year ended June 30, 2022. “CNS kicked off Q3 2022 with approximately $9 million in cash, and working capital of approximately $10.3 million, which, it is confident, will fund its operations into the 2023 calendar year. Currently, the company is exploring the full potential of its lead product candidate, Berubicin. Results from clinical studies over the last six months have proven fruitful,…

Site Search

Company Search

Category: QualityStocksNewsBreaks